Efficacy of autologous peripheral blood stem cell (PBSC) harvest and engraftment after ablative chemotherapy in pediatric patients

Paul R. Haut*, Susan Cohn, Elaine R Morgan, Maureen Hubbell, Karina Danner-Koptik, Marie Olszewski, Mary Schaff, Morris Kletzel

*Corresponding author for this work

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Thirty-five pediatric patients, 1-16 years of age (median 6.3 years), with neoplastic solid tumors (n=32) or acute leukemia (n=3) underwent peripheral blood stem cell (PBSC) harvest and transplantation at Children's Memorial Hospital between September 1992 and April 1997. A median of four phereses were performed on each patient. Blood samples from 34 of the 35 patients were harvested through existing double-lumen central catheters, using either a Fenwal CS-3000 or COBE Spectra pheresis machine. The pheresis procedures were well tolerated overall. A median of 3.7×106/kg CD34+ cells were infused (range, 0.2-15.5×106/kg), and all patients engrafted. The median time to an absolute neutrophil count >500/μL was 13 days (range, 9-44 days) and to a platelet count >20,000/μL was 21 days (range, 9-210 days). Two patients died from transplant-related complications. Patients were discharged from the hospital after a median of 22 days (range, 15-64 days). Twenty of the 35 patients are alive, 17 of whom remain disease-free with a median follow-up of 1144 days. According to this study, PBSCs can be successfully harvested and re-infused for marrow reconstitution after myeloablative therapy in children for a variety of pediatric malignancies with low morbidity and mortality.

Original languageEnglish (US)
Pages (from-to)38-42
Number of pages5
JournalBiology of Blood and Marrow Transplantation
Volume4
Issue number1
DOIs
StatePublished - Jan 1 1998

Fingerprint

Pediatrics
Drug Therapy
Blood Component Removal
Peripheral Blood Stem Cell Transplantation
Peripheral Blood Stem Cells
Platelet Count
Neoplasms
Leukemia
Neutrophils
Catheters
Bone Marrow
Morbidity
Transplants
Mortality
Therapeutics

Keywords

  • PBSC
  • Pediatrics
  • Transplant

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Haut, Paul R. ; Cohn, Susan ; Morgan, Elaine R ; Hubbell, Maureen ; Danner-Koptik, Karina ; Olszewski, Marie ; Schaff, Mary ; Kletzel, Morris. / Efficacy of autologous peripheral blood stem cell (PBSC) harvest and engraftment after ablative chemotherapy in pediatric patients. In: Biology of Blood and Marrow Transplantation. 1998 ; Vol. 4, No. 1. pp. 38-42.
@article{a1e116437ebb4b539eb8485151ada1d4,
title = "Efficacy of autologous peripheral blood stem cell (PBSC) harvest and engraftment after ablative chemotherapy in pediatric patients",
abstract = "Thirty-five pediatric patients, 1-16 years of age (median 6.3 years), with neoplastic solid tumors (n=32) or acute leukemia (n=3) underwent peripheral blood stem cell (PBSC) harvest and transplantation at Children's Memorial Hospital between September 1992 and April 1997. A median of four phereses were performed on each patient. Blood samples from 34 of the 35 patients were harvested through existing double-lumen central catheters, using either a Fenwal CS-3000 or COBE Spectra pheresis machine. The pheresis procedures were well tolerated overall. A median of 3.7×106/kg CD34+ cells were infused (range, 0.2-15.5×106/kg), and all patients engrafted. The median time to an absolute neutrophil count >500/μL was 13 days (range, 9-44 days) and to a platelet count >20,000/μL was 21 days (range, 9-210 days). Two patients died from transplant-related complications. Patients were discharged from the hospital after a median of 22 days (range, 15-64 days). Twenty of the 35 patients are alive, 17 of whom remain disease-free with a median follow-up of 1144 days. According to this study, PBSCs can be successfully harvested and re-infused for marrow reconstitution after myeloablative therapy in children for a variety of pediatric malignancies with low morbidity and mortality.",
keywords = "PBSC, Pediatrics, Transplant",
author = "Haut, {Paul R.} and Susan Cohn and Morgan, {Elaine R} and Maureen Hubbell and Karina Danner-Koptik and Marie Olszewski and Mary Schaff and Morris Kletzel",
year = "1998",
month = "1",
day = "1",
doi = "10.1053/bbmt.1998.v4.pm9701390",
language = "English (US)",
volume = "4",
pages = "38--42",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "1",

}

Efficacy of autologous peripheral blood stem cell (PBSC) harvest and engraftment after ablative chemotherapy in pediatric patients. / Haut, Paul R.; Cohn, Susan; Morgan, Elaine R; Hubbell, Maureen; Danner-Koptik, Karina; Olszewski, Marie; Schaff, Mary; Kletzel, Morris.

In: Biology of Blood and Marrow Transplantation, Vol. 4, No. 1, 01.01.1998, p. 38-42.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy of autologous peripheral blood stem cell (PBSC) harvest and engraftment after ablative chemotherapy in pediatric patients

AU - Haut, Paul R.

AU - Cohn, Susan

AU - Morgan, Elaine R

AU - Hubbell, Maureen

AU - Danner-Koptik, Karina

AU - Olszewski, Marie

AU - Schaff, Mary

AU - Kletzel, Morris

PY - 1998/1/1

Y1 - 1998/1/1

N2 - Thirty-five pediatric patients, 1-16 years of age (median 6.3 years), with neoplastic solid tumors (n=32) or acute leukemia (n=3) underwent peripheral blood stem cell (PBSC) harvest and transplantation at Children's Memorial Hospital between September 1992 and April 1997. A median of four phereses were performed on each patient. Blood samples from 34 of the 35 patients were harvested through existing double-lumen central catheters, using either a Fenwal CS-3000 or COBE Spectra pheresis machine. The pheresis procedures were well tolerated overall. A median of 3.7×106/kg CD34+ cells were infused (range, 0.2-15.5×106/kg), and all patients engrafted. The median time to an absolute neutrophil count >500/μL was 13 days (range, 9-44 days) and to a platelet count >20,000/μL was 21 days (range, 9-210 days). Two patients died from transplant-related complications. Patients were discharged from the hospital after a median of 22 days (range, 15-64 days). Twenty of the 35 patients are alive, 17 of whom remain disease-free with a median follow-up of 1144 days. According to this study, PBSCs can be successfully harvested and re-infused for marrow reconstitution after myeloablative therapy in children for a variety of pediatric malignancies with low morbidity and mortality.

AB - Thirty-five pediatric patients, 1-16 years of age (median 6.3 years), with neoplastic solid tumors (n=32) or acute leukemia (n=3) underwent peripheral blood stem cell (PBSC) harvest and transplantation at Children's Memorial Hospital between September 1992 and April 1997. A median of four phereses were performed on each patient. Blood samples from 34 of the 35 patients were harvested through existing double-lumen central catheters, using either a Fenwal CS-3000 or COBE Spectra pheresis machine. The pheresis procedures were well tolerated overall. A median of 3.7×106/kg CD34+ cells were infused (range, 0.2-15.5×106/kg), and all patients engrafted. The median time to an absolute neutrophil count >500/μL was 13 days (range, 9-44 days) and to a platelet count >20,000/μL was 21 days (range, 9-210 days). Two patients died from transplant-related complications. Patients were discharged from the hospital after a median of 22 days (range, 15-64 days). Twenty of the 35 patients are alive, 17 of whom remain disease-free with a median follow-up of 1144 days. According to this study, PBSCs can be successfully harvested and re-infused for marrow reconstitution after myeloablative therapy in children for a variety of pediatric malignancies with low morbidity and mortality.

KW - PBSC

KW - Pediatrics

KW - Transplant

UR - http://www.scopus.com/inward/record.url?scp=0031610287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031610287&partnerID=8YFLogxK

U2 - 10.1053/bbmt.1998.v4.pm9701390

DO - 10.1053/bbmt.1998.v4.pm9701390

M3 - Article

VL - 4

SP - 38

EP - 42

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 1

ER -